Posted by Michael Wonder on 03 Aug 2017
Sandoz Erelzi (etanercept) receives positive reimbursement recommendation from Common Drug Review for treatment of multiple inflammatory diseases
2 August 2017 - Positive recommendation moves Erelzi closer to federal, provincial and territorial drug plan reimbursement.
Sandoz announced today that The Canadian Drug Expert Committee as part of the Common Drug Review process has issued a positive drug reimbursement recommendation for Erelzi (etanercept).
Health Canada granted Erelzi a Notice of Compliance in April 2017. In Canada, Erelzi is approved for the treatment of ankylosing spondylitis, and for the treatment of moderately to severely active rheumatoid arthritis in adults, and polyarticular juvenile idiopathic arthritis in patients aged 4 years or older.
This positive recommendation is based on Erelzi being reimbursed in a manner similar to Enbrel and for use in patients for whom etanercept is considered to be the most appropriate treatment option.
